ArriVent BioPharma, Inc. (AVBP) vs MiMedx Group, Inc. (MDXG)

A side-by-side comparison of ArriVent BioPharma, Inc. and MiMedx Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AVBP vs MDXG

growth of $100 · dividends reinvested · last 3y
AVBP +42.3% (+12.5%/yr)MDXG -43.9% (-17.5%/yr)AVBP compounded faster over this window
50100150Start $10020252026$142$56
AVBP MDXG

AVBP vs MDXG: by the numbers

  • •AVBP is the larger company ($703M vs $673M market cap).
  • •MDXG is profitable (1.76% net margin) while AVBP runs a net loss (0.00%).

Metrics side by side

Valuation

MetricAVBPMDXG
P/E ratioN/A115.50
P/S ratioN/A1.90
P/B ratio1.923.12
EV / EBITDAN/A26.41
FCF yieldN/A6.03%

Profitability

MetricAVBPMDXG
Gross margin0.00%78.85%
Operating margin0.00%15.26%
Net margin0.00%1.76%
ROE-44.63%2.89%
ROIC-47.96%1.97%

Growth (annualized)

MetricAVBPMDXG
Revenue CAGR (5Y)N/A6.36%
Total return CAGR (5Y)N/A-4.94%

Frequently asked

Is AVBP or MDXG more profitable?
MDXG runs the higher net margin — AVBP at 0.00% versus MDXG at 1.76%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.